Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 3, 2007, Pages 247-256

  Daull, Philippe ^a   Jeng, Arco Y ^b   Battistini, Bruno ^a,c  

^a Millenia Hope Inc   (Canada)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Angiotensin; Angiotensin converting enzyme; Bradykinin; Endothelin; Endothelin converting enzyme; Natriuretic peptides; Neprylisin; Vasopeptide inhibitors

Indexed keywords

2 (4 BIPHENYLYL) 1 (1H TETRAZOL 5 YL)ETHYLAMINOMETHYLPHOSPHONIC ACID; 7 (2 ACETYLTHIO 3 PHENYLPROPIONAMIDO) 1,2,3,4,6,7,8,12B OCTAHYDRO 6 OXOPYRIDO[2,1 A][2]BENZAZEPINE 4 CARBOXYLIC ACID; ANTIFIBROTIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; AVE 7688; CAPTOPRIL; CGS 31447; CGS 34043; CGS 34226; CGS 35601; CGS 37808; DAGLUTRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN CONVERTING ENZYME INHIBITOR; FASIDOTRIL; GEMOPATRILAT; GW 660511X; GW 796406; IMIDAPRIL; N (2 MERCAPTOMETHYL 3 PHENYLBUTYRYL)ALANINE; N [[1 (2 ACETYLTHIO 3 METHYL 1 OXOBUTYLAMINO) 1 CYCLOPENTYL]CARBONYL] O METHYLTYROSINE ETHYL ESTER; NEPRYLISIN INHIBITOR; OMAPATRILAT; SA 7060; SAMPATRILAT; SCH 54470; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPEPTIDASE INHIBITOR; Z 13752A;

ABSENCE OF SIDE EFFECTS; ANGIONEUROTIC EDEMA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUGHING; DAHL SALT SENSITIVE RAT; DIABETIC NEPHROPATHY; DIZZINESS; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TARGETING; EDEMA; HEART INFARCTION; HUMAN; HYPERTENSION; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SPONTANEOUSLY HYPERTENSIVE RAT; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPARTIC ENDOPEPTIDASES; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; ENZYME INHIBITORS; HUMANS; HYPERTENSION; METALLOENDOPEPTIDASES; NEPRILYSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 34548746991     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31813c6ca5     Document Type: Review

References (82)

1. Kaplan NM, Opie LH. Controversies in cardiology 2. Controversies in hypertension. Lancet. 2006;367:168-176.
2. American Heart Association. Heart Disease and Stroke Statistics. Dallas: American Heart Association; 2005.
3. Natesh R, Schwager SL, Sturrock ED, et al. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature. 2003;421:551-554.
4. Oefner C, D'Arcy A, Hennig M, et al. Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon. J Mol Biol. 2000;296:341-349.
5. Bur D, Dale GE, Oefner C. A three-dimensional model of endothelin-converting enzyme (ECE) based on the X-ray structure of neutral endopeptidase 24.11 (NEP). Protein Eng. 2001;14:337-341.
6. Worthley MI, Corti R, Worthley SG. Vasopeptidase inhibitors: will they have a role in clinical practice? Br J Clin Pharmacol. 2004;57:27-36.
7. Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit. 2005;11:RA194-RA205.
8. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science. 1977;196:441-444.
9. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
10. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
11. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53.
12. Fleming I, Kohlstedt K, Busse R. New fACEs to the renin-angiotensin system. Physiology (Bethesda). 2005;20:91-95.
13. Kohlstedt K, Shoghi F, Muller-Esterl W, et al. CK2 phosphorylates the angiotensin-converting enzyme and regulates its retention in the endothelial cell plasma membrane. Circ Res. 2002;91:749-756.
14. Kohlstedt K, Brandes RP, Muller-Esterl W, et al. Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells. Circ Res. 2004;94:60-67.
15. Kohlstedt K, Busse R, Fleming I. Signaling via the angiotensin-converting enzyme enhances the expression of cyclooxygenase-2 in endothelial cells. Hypertension. 2005;45:126-132.
16. Sakamoto K, Sugimoto K, Sudoh T, et al. Different effects of imidapril and enalapril on aminopeptidase P activity in the mouse trachea. Hypertens Res. 2005;28:243-247.
17. Overlack A. ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management. Drug Saf. 1996;15:72-78.
18. Lalloo UG, Barnes PJ, Chung KF. Pathophysiology and clinical presentations of cough. J Allergy Clin Immunol. 1996;98:S91-S96.
19. Takahashi T, Yamaguchi E, Furuya K, et al. The ACE gene polymorphism and cough threshold for capsaicin after cilazapril usage. Respir Med. 2001;95:130-135.
20. Mukae S, Itoh S, Aoki S, et al. Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough. J Hum Hypertens. 2002;16:857-863.
21. Greaves M, Lawlor F. Angioedema: manifestations and management. J Am Acad Dermatol. 1991;25:155-161.
22. Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol. 2005;53:373-388.
23. Brown NJ, Ray WA, Snowden M, et al. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996;60:8-13.
24. Cugno M, Nussberger J, Cicardi M, et al. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol. 2003;3:311-317.
25. Molinaro G, Cugno M, Perez M, et al. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. J Pharmacol Exp Ther. 2002;303:232-237.
26. Lefebvre J, Murphey LJ, Hartert TV, et al. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension. 2002;39:460-464.
27. Adam A, Cugno M, Molinaro G, et al. Aminopeptidase P in individualswith a history of angio-oedema on ACE inhibitors. Lancet. 2002;359:2088-2089.
28. Sigler C, Annis K, Cooper K, et al. Examination of baseline levels of carboxypeptidase N and complement components as potential predictors of angioedema associated with the use of an angiotensin-converting enzyme inhibitor. Arch Dermatol. 1997;133:972-975.
29. Favrat B, Burnier M, Nussberger J, et al. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens. 1995;13:797-804.
30. Graf K, Koehne P, Grafe M, et al. Regulation and differential expression of neutral endopeptidase 24.11 in human endothelial cells. Hypertension. 1995;26:230-235.
31. Dussaule JC, Stefanski A, Bea ML, et al. Characterization of neutral endopeptidase in vascular smooth muscle cells of rabbit renal cortex. Am J Physiol. 1993;264:F45-F52.
32. Stephenson SL, Kenny AJ. Metabolism of neuropeptides. Hydrolysis of the angiotensins, bradykinin, substance P and oxytocin by pig kidney microvillar membranes. Biochem J. 1987;241:237-247.
33. Lang CC, Motwani JG, Coutie WJ, et al. Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism. Clin Sci (Lond). 1992;82:619-623.
34. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J. 1993;291:83-88.
35. Campbell DJ. Vasopeptidase inhibition: a double-edged sword? Hypertension. 2003;41:383-389.
36. Corti R, Burnett JC Jr, Rouleau JL, et al. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation. 2001;104:1856-1862.
37. Stasch JP, Hirth-Dietrich C, Ganten D, et al. Renal and antihypertensive effects of neutral endopeptidase inhibition in transgenic rats with an extra renin gene. Am J Hypertens. 1996;9:795-802.
38. Dussaule JC, Grange JD, Wolf JP, et al. Effect of sinorphan, an enkephalinase inhibitor, on plasma atrial natriuretic factor and sodium urinary excretion in cirrhotic patients with ascites. J Clin Endocrinol Metab. 1991;72:653-669.
39. Zhang X, Recchia FA, Bernstein R, et al. Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure. J Pharmacol Exp Ther. 1999;288:742-751.
40. Fink CA, Carlson JE, McTaggart PA, et al. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem. 1996;39:3158-3168.
41. Trippodo NC, Panchal BC, Fox M. Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure. J Pharmacol Exp Ther. 1995;272:619-627.
42. Gonzalez W, Beslot F, Laboulandine I, et al. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction. J Pharmacol Exp Ther. 1996;278:573-581.
43. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet. 2000;356:608-609.
44. Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angiooedema. Lancet. 1998;351:1693-1697.
45. Trippodo NC, Robl JA, Asaad MM, et al. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens. 1998;11:363-372.
46. Jeng AY, Savage P, Beil ME, et al. CGS 34226, a thiol-based dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11. Clin Sci (Lond). 2002;103:98S-101S.
47. Kentsch M, Otter W, Drummer C, et al. Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure. Eur J Clin Pharmacol. 1996;51:269-272.
48. Tabrizchi, R. SLV-306. Solvay. Curr Opin Investig Drugs. 2003;4:329-332.
49. Dickstein K, De Voogd HJ, Miric MP, et al. Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol. 2004;94:237-239.
50. Vemulapalli S, Chintala M, Stamford A, et al. Renal effects of SCH 54470: a triple inhibitor of ECE, ACE and NEP. Cardiovasc Drug Rev. 1997;15:260-272.
51. Trapani AJ, Beil ME, Bruseo CW, et al. CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme. J Cardiovasc Pharmacol. 2004;44:S211-S215.
52. Daull P, Benrezzak O, Arsenault D, et al. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats. Am J Hypertens. 2005;18:1606-1613.
53. Inguimbert N, Poras H, Teffo F, et al. N-[2-(Indan-1-yl)-3- mercaptopropionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): in vitro and in vivo activities. Bioorg Med Chem Lett. 2002;12:2001-2005.
54. Battistini B, Daull P, Jeng AY. CGS 35601, a triple inhibitor of angiotensin-converting enzyme, neutral endopeptidase and endothelin converting enzyme. Cardiovasc Drug Rev. 2005;23:317-330.
55. Daull P, Blouin A, Belleville K, et al. CGS 35601, a triple vasopeptidase inhitor reduces hypertension in instrumented Dahl salt-sensitive rats fed a high-salt diet. Exp Biol Medicine. 2006;231:830-833.
56. Sulpizio AC, Pullen MA, Edwards RM, et al. Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005;315:1306-1313.
57. Daull P, Lepage R, Benrezzak O, et al. The first pre-clinical pharmacotoxicological safety assessment of CGS 35601, a triple vasopeptidase inhibitor, in chronically instrumented, conscious and unrestrained spontaneously hypertensive rats. Drug Chem Toxicol. 2006;29:183-202.
58. Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 international consensus algorithm for the diagnostic, therapy, and management of hereditary angioedema. J Allergy Clin Immunol. 2004;114:629-637.
59. Duan QL, Nikpoor B, Dube MP, et al. Avariant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am J Hum Genet. 2005;77:617-626.
60. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106:920-926.
61. Laverman GD, Van Goor H, Henning RH, et al. Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes. Kidney Int. 2003;63:64-71.
62. Hubner RA, Kubota E, Casley DJ, et al. In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat. J Hypertens. 2001;19:941-946.
63. Schafer S, Linz W, Vollert H, et al. The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy. Diabetologia. 2004;47:98-103.
64. Emmons GT, Argenti R, Martin LL, et al. Pharmacokinetics of M100240 and MDL 100,173, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteers. J Clin Pharmacol. 2004;44:901-905.
65. French JF, Flynn GA, Giroux EL, et al. Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase. J Pharmacol Exp Ther. 1994;268:180-186.
66. Allikmets K. Sampatrilat Shire. Curr Opin Investig Drugs. 2002;3:578-581.
67. Maki T, Nasa Y, Tanonaka K, et al. Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation. J Pharmacol Exp Ther. 2003;305:97-105.
68. Fournie-Zaluski MC, Gonzalez W, Turcaud S, et al. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension. Proc Natl Acad Sci USA. 1994;91:4072-4076.
69. Heudi O, Ramirez-Molina C, Marshall P, et al. Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/NEP inhibitors GW660511X and omapatrilat. J Pept Sci. 2002;8:591-600.
70. Bani M, Colantoni A, Guillaume M, et al. A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers. Br J Clin Pharmacol. 2000;50:338-349.
71. Kuro T, Okahara A, Nose M, et al. Effects of SA7060, a novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, on deoxycorticosterone acetate-salt-induced hypertension in rats. Biol Pharm Bull. 2000;23:820-825.
72. Ozdener F, Ozdemir V. Fasidotril Eli Lilly. Curr Opin Investig Drugs. 2003;4:1113-1119.
73. Laurent S, Boutouyrie P, Azizi M, et al. Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans. Hypertension. 2000;35:1148-1153.
74. Chatelain RE, Ghai RD, Trapani AJ, et al. Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11. J Pharmacol Exp Ther. 1998;284:974-982.
75. Emoto N, Raharjo SB, Isaka D, et al. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats. Hypertension. 2005;45:1145-1152.
76. Mulder P, Barbier S, Monteil C, et al. Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECENEP inhibition in rats with congestive heart failure. J Cardiovasc Pharmacol. 2004;43:489-494.
77. De Lombaert S, Blanchard L, Stamford LB, et al. Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action. J Med Chem. 2000;43:488-504.
78. Trapani AJ, Beil ME, Bruseo CW, et al. Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats. Clin Sci (Lond). 2002;103:102S-106S.
79. Trapani AJ, De Lombaert S, Beil ME, et al. CGS 34043: a nonpeptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11. Life Sci. 2000;67:1025-1033.
80. Shetty SS, Savage P, DelGrande D, et al. Characterization of CGS 31447, a potent and nonpeptidic endothelin-converting enzyme inhibitor. J Cardiovasc Pharmacol. 1998;31:S68-S70.
81. Kaneko Y, Herrera VL, Didishvili T, et al. Sex-specific effects of dual ET-1/ANG II receptor (Dear) variants in Dahl salt-sensitive/resistant hypertension rat model. Physiol Genomics. 2005;20:157-164.
82. Glorioso N, Herrera VL, Bagamasbad P, et al. Association of ATP1A1 and Dear single-nucleotide polymorphism haplotypes with essential hypertension: sex-specific and haplotype-specific effects. Circ Res. 2007;100:1522-1529.